Randomized trial · people
NMN: raised blood NAD over 60 days in 80 middle-aged adults
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In healthy middle-aged adults, daily NMN up to 900 mg raised blood NAD and was well tolerated over 60 days, with the largest NAD and walking gains in the 600 mg and 900 mg arms.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 80
- Published
- 2023
- Journal
- Geroscience
What they tested
The team tested whether daily oral NMN raises blood NAD levels in a dose-dependent way, and whether it is safe and affects physical performance and health measures.
How the study was done
A randomized, double-blind, placebo-controlled trial run at several centers in 80 healthy middle-aged adults. Each person took placebo (a dummy dose with no NMN) or 300 mg, 600 mg or 900 mg of NMN once daily by mouth for 60 days.

What they found
All 80 people finished the trial. Blood NAD rose in all three NMN arms at day 30 and day 60 compared with placebo and with starting levels (all p ≤ 0.001), and it was highest in the 600 mg and 900 mg arms. Gains in six-minute walking distance were larger in all NMN arms than with placebo at both time points (all p < 0.01), longest in the 600 mg and 900 mg arms. Blood biological age, an estimate from the Aging.Ai 3.0 calculator, went up in the placebo arm and held steady in the NMN arms (all p < 0.05), while HOMA-IR, a measure of insulin resistance, did not differ from placebo. No safety issues showed up in side effects, lab tests or clinical checks, and SF-36 general health scores improved more than with placebo in all NMN arms except the 300 mg arm at day 30.
What it doesn’t show
This was a small, short trial of 60 days in healthy middle-aged adults, so it does not show long-term effects or results in older or sick people. Results came from a per-protocol analysis, and biological age was a calculator estimate rather than a direct health outcome.
The paper
Yi et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023.
The compound
More studies on NMN
- NMN: no significant benefit on blood sugar or lipids in pooled trialsMeta-analysis · people · 2024
- NMN raised serum nicotinamide over 12 weeks in middle-aged adultsRandomized trial · people · 2023
- NMN supplements raised blood NAD+ levels in healthy older menRandomized trial · people · 2022
- NMN raised muscle insulin sensitivity in women with prediabetesRandomized trial · people · 2021
- NMN: aerobic gains at 600 and 1200 mg/day in amateur runnersRandomized trial · people · 2021
- Every study on NMN
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.